Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater increase » year increase (Expand Search)
better decrease » greater decrease (Expand Search), teer decrease (Expand Search), between decreased (Expand Search)
Showing 921 - 940 results of 24,549 for search '(( significant decrease decrease ) OR ( significantly ((better decrease) OR (greater increase)) ))', query time: 0.51s Refine Results
  1. 921
    Phagocytosis of fluorescent latex beads (2 μm) by infected PEMs, BMMs and THP-1 in the three culture systems (static, slow flow rate 1.45 x 10− − 9 m/s and fast flow rate 1.23 x 10− − 7 m/s).

    Phagocytosis of fluorescent latex beads (2 μm) by infected PEMs, BMMs and THP-1 in the three culture systems (static, slow flow rate 1.45 x 10− − 9 m/s and fast flow rate 1.23 x 10... by Alaa Riezk (7037297)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 922
    Macropinocytosis of pHrodo Red dextran by infected PEMs, BMMs and THP-1 at the three culture systems (static, slow flow rate 1.45 x 10− − 9 m/s and fast flow rate 1.23 x 10− − 7 m/s).

    Macropinocytosis of pHrodo Red dextran by infected PEMs, BMMs and THP-1 at the three culture systems (static, slow flow rate 1.45 x 10− − 9 m/s and fast flow rate 1.23 x 10− − 7 m/... by Alaa Riezk (7037297)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 923
    Schematic overview of evaluation of the anti-leishmanial activity in static and flow culture systems [

    Schematic overview of evaluation of the anti-leishmanial activity in static and flow culture systems [ by Alaa Riezk (7037297)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 924
    <i>In vitro</i> activity of chitosan solution and nanoparticles against <i>L. major</i> amastigotes in RPMI-1640 (pH = 6.5) at different flow rates.

    <i>In vitro</i> activity of chitosan solution and nanoparticles against <i>L. major</i> amastigotes in RPMI-1640 (pH = 6.5) at different flow rates. by Alaa Riezk (7037297)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 925
    Dose-response curve of the activity of chitosan solution (A), blank chitosan-TPP nanoparticles (B), AmB loaded chitosan-TPP nanoparticles (C) and AmB solution (pure) (D) against L.

    Dose-response curve of the activity of chitosan solution (A), blank chitosan-TPP nanoparticles (B), AmB loaded chitosan-TPP nanoparticles (C) and AmB solution (pure) (D) against L. by Alaa Riezk (7037297)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 926
    Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It includes the number of participants in each group, frequency, intensity, and duration of chills, along with demographics such as gender, age, race, education level, and income. Statistical significance (p-value) is also provided for each category.

    Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It... by Felix Alexandre Schoeller (20988295)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 927
    <i>N. parisii</i> infection is not significantly changed in <i>C. elegans</i> sphingolipid biosynthesis mutants.

    <i>N. parisii</i> infection is not significantly changed in <i>C. elegans</i> sphingolipid biosynthesis mutants. by Hala Tamim El Jarkass (16625309)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 928
    Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1.

    Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1. by Mucahit Gemici (21519313)

    Published 2025
    Save to List
    Saved in:
  9. 929
    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2.

    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

    Published 2025
    Save to List
    Saved in:
  10. 930
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 931
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 932
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 933
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 934
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 935
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 936
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 937
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 938
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 939
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 940
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: